We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

17 hedge funds and large institutions have $33.1M invested in Palvella Therapeutics in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

6% less funds holding

Funds holding: 18 → 17 (-1)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

18% less capital invested

Capital invested by funds: $40.5M → $33.1M (-$7.44M)

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
7
Increased
2
Reduced
2
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SM
Sabby Management
Florida
+$176K
2
DCM
DAFNA Capital Management
California
+$88.3K
3
OC
Oppenheimer & Co
New York
+$78.5K
4
Creative Planning
Creative Planning
Kansas
+$8.86K
5
Walleye Trading
Walleye Trading
New York
+$5.63K

Top Sellers

1
LOAMU
Lombard Odier Asset Management (USA)
New York
-$380K
2
Millennium Management
Millennium Management
New York
-$175K
3
EA
Emerald Advisers
Pennsylvania
-$129K
4
SIM
Spark Investment Management
New York
-$69K
5
TC
TFS Capital
Pennsylvania
-$54K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$13.8M – – –
TCM
2
Tekla Capital Management
Massachusetts
$7.31M – – –
LOAMU
3
Lombard Odier Asset Management (USA)
New York
$5M -$380K -2,698 -8%
OFM
4
Omega Fund Management
Massachusetts
$4.72M – – –
SFM
5
Sphera Funds Management
Israel
$1.54M – – –
SM
6
Sabby Management
Florida
$333K +$176K +1,248 +133%
Millennium Management
7
Millennium Management
New York
$113K -$175K -1,247 -63%
OC
8
Oppenheimer & Co
New York
$113K +$78.5K +558 +297%
DCM
9
DAFNA Capital Management
California
$95K +$88.3K +628 New
Bank of America
10
Bank of America
North Carolina
$19K – – –
Creative Planning
11
Creative Planning
Kansas
$10K +$8.86K +63 New
Walleye Trading
12
Walleye Trading
New York
$6K +$5.63K +40 New
Manulife (Manufacturers Life Insurance)
13
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5K +$4.64K +33 New
AIM
14
Acrospire Investment Management
Illinois
$3K +$2.53K +18 New
TRCT
15
Tower Research Capital (TRC)
New York
$2K +$1.69K +12 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$24 – – –
EA
17
Emerald Advisers
Pennsylvania
– -$129K -702 Closed
SIM
18
Spark Investment Management
New York
– -$69K -378 Closed
TC
19
TFS Capital
Pennsylvania
– -$54K -295 Closed
HighTower Advisors
20
HighTower Advisors
Illinois
– -$34K -188 Closed
VKH
21
Virtu KCG Holdings
New York
– -$33K -183 Closed
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
– -$29K -157 Closed
Nomura Holdings
23
Nomura Holdings
Japan
– -$25K -138 Closed
UBS Group
24
UBS Group
Switzerland
– -$9K -51 Closed
Citigroup
25
Citigroup
New York
– +$281 +2 New

PVLA Hedge Fund Activity: Q1 2016 in Review

17 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2016, worth a combined $33.1M — down 18% from $40.5M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PVLA and 7 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Sabby Management, adding an estimated $176K. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $380K.

  • 17 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2016, down from 18 in Q4 2015.
  • Funds reported $33.1M of Palvella Therapeutics stock for Q1 2016, down 18% quarter-over-quarter.
  • 7 funds opened new Palvella Therapeutics positions in Q1 2016 and 8 closed out, a net change of -1 holder.
  • The largest Palvella Therapeutics buyer in Q1 2016 was Sabby Management, an estimated $176K added.
  • The largest Palvella Therapeutics seller in Q1 2016 was Lombard Odier Asset Management (USA), an estimated $380K sold.

Based on aggregated 13F filings for Q1 2016.